Open AccessImpact of metformin on anti‐Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial
Author(s) -
Madsen Helen N.,
Lauszus Finn F.,
Trolle Birgitta,
Ingerslev Hans J.,
Tørring Niels
Publication year - 2015
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1111/aogs.12605
Subject(s) - metformin , polycystic ovary , medicine , placebo , anti müllerian hormone , endocrinology , ovary , randomized controlled trial , hormone , gynecology , obesity , diabetes mellitus , insulin resistance , alternative medicine , pathology
Conclusions on the effect of metformin on circulating anti‐Müllerian hormone ( AMH ) levels in women with polycystic ovary syndrome ( PCOS ) are ambiguous. We performed a secondary analysis of a randomized, double‐blind, placebo‐controlled cross‐over trial. Fifty‐six women with hyperandrogenemic PCOS were included. Each woman served as her own control receiving a daily dose of either 1700 mg metformin or placebo for 6 months. After a 3‐month wash‐out period they received the opposite treatment. The decrease in AMH from a median of 49.5 to 46.9 pmol/L after 6 months on metformin was overall not significant ( p = 0.81), nor were changes in obese women (from 49.5 to 38.2 pmol/L; p = 0.53). Comparing individual metformin/placebo AMH values, a small absolute decrease of 9.3 pmol/L ( p = 0.03) was observed in obese women after 6 months relative to baseline, suggesting a trend towards decreasing values after metformin treatment, mainly in obese women.